Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

53 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Digoxin use in patients with atrial fibrillation and adverse cardiovascular outcomes: a retrospective analysis of the Rivaroxaban Once Daily Oral Direct Factor Xa Inhibition Compared with Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation (ROCKET AF).
Washam JB, Stevens SR, Lokhnygina Y, Halperin JL, Breithardt G, Singer DE, Mahaffey KW, Hankey GJ, Berkowitz SD, Nessel CC, Fox KA, Califf RM, Piccini JP, Patel MR; ROCKET AF Steering Committee and Investigators. Washam JB, et al. Lancet. 2015 Jun 13;385(9985):2363-70. doi: 10.1016/S0140-6736(14)61836-5. Epub 2015 Mar 6. Lancet. 2015. PMID: 25749644
Dabigatran for periprocedural anticoagulation following radiofrequency ablation for atrial fibrillation: a meta-analysis of observational studies.
Steinberg BA, Hasselblad V, Atwater BD, Bahnson TD, Washam JB, Alexander JH, Daubert JP, Piccini JP. Steinberg BA, et al. Among authors: washam jb. J Interv Card Electrophysiol. 2013 Sep;37(3):213-21. doi: 10.1007/s10840-013-9813-7. Epub 2013 Jul 24. J Interv Card Electrophysiol. 2013. PMID: 23881249 Free PMC article.
Edoxaban and the need for outcomes-based NOAC dosing.
Patel MR, Washam JB. Patel MR, et al. Among authors: washam jb. Lancet. 2015 Jun 6;385(9984):2232-3. doi: 10.1016/S0140-6736(14)62289-3. Epub 2015 Mar 11. Lancet. 2015. PMID: 25769359 No abstract available.
Polypharmacy and the Efficacy and Safety of Rivaroxaban Versus Warfarin in the Prevention of Stroke in Patients With Nonvalvular Atrial Fibrillation.
Piccini JP, Hellkamp AS, Washam JB, Becker RC, Breithardt G, Berkowitz SD, Halperin JL, Hankey GJ, Hacke W, Mahaffey KW, Nessel CC, Singer DE, Fox KA, Patel MR. Piccini JP, et al. Among authors: washam jb. Circulation. 2016 Jan 26;133(4):352-60. doi: 10.1161/CIRCULATIONAHA.115.018544. Epub 2015 Dec 16. Circulation. 2016. PMID: 26673560 Free article. Clinical Trial.
Response by Piccini et al to Letters Regarding Article, "Polypharmacy and the Efficacy and Safety of Rivaroxaban Versus Warfarin in the Prevention of Stroke in Patients With Nonvalvular Atrial Fibrillation".
Piccini JP, Hellkamp AS, Washam JB, Becker RC, Breithardt G, Berkowitz SD, Halperin JL, Hankey GJ, Hacke W, Mahaffey KW, Nessel CC, Singer DE, Fox KA, Patel MR. Piccini JP, et al. Among authors: washam jb. Circulation. 2016 Jul 12;134(2):e7-8. doi: 10.1161/CIRCULATIONAHA.116.022737. Circulation. 2016. PMID: 27400902 Free article. No abstract available.
53 results